• Sharing the role of technology and partnerships in the design & recruitment of studies.
• Highlighting adaptive trial designs, decentralized models, and inclusive recruitment strategies.
• Exploring how smarter trial design accelerates approval, reduces risk, and improves real-world outcomes.

• Demystifying product-market fit in the context of digital health, where clinical need, usability, and reimbursement must align.
• Identifying key indicators—user adoption, engagement, and outcomes—that show readiness to scale.
• Strategies for translating validated need into scalable, sustainable digital health solutions.

• Discuss strategies for trial design that account for hormonal fluctuations, comorbidities, and age-related variables unique to the menopausal transition.
• Highlight regulatory, industry, and advocacy efforts that are pushing for menopause-specific representation in therapeutic areas beyond just women’s health.
• Sharing advancements to educate clinical trial patients about menopause.

• How can pre-trial screening effectively predict side effects and symptoms associated with reproductive therapeutics.
• What are the appropriate safety profiles to apply for endometriosis, PCOS, and fibroids.

• Expanding access to mammograms and diagnostics in underserved communities.
• Personalizing Risk Assessment & Early Detection, how AI, genetic testing, and targeted outreach are improving outcomes.
• The adoption of innovation in breast & cervical cancer screening centred around patient centricity.

• How the demand for menopause-focused functional foods, probiotics, and supplements is shaping new business opportunities.
• Sharing insights into how nutrition and food as medicine links bone, heart, and brain health in menopause and the opportunity to address these health outcomes through wellness.
• Expanding access to menopause nutrition solutions through pharmacies, e-commerce, consumer wellness, and employer plans.

Demonstrate how AI-driven initiatives - like predictive modelling and automated inspection -translate into measurable outcomes (e.g., defect reduction, shorter batch release cycles) that justify capital investment and cross-functional prioritization